Literature DB >> 22997356

Transanal excision with radiation therapy for rectal adenocarcinoma.

Nathan Tennyson1, William M Mendenhall, Christopher G Morris, Emina H Huang, Robert A Zlotecki.   

Abstract

OBJECTIVE: To evaluate the efficacy of transanal excision (TAE) combined with radiotherapy for rectal adenocarcinoma, assess the ability of pretreatment endoscopic ultrasound (EUS) to predict failures, and determine the prognostic value of downstaging and complete pathological response.
DESIGN: Retrospective outcomes study.
SETTING: Radiation oncology clinic. PARTICIPANTS: Thirty-eight patients with rectal adenocarcinoma.
METHODS: The medical records of patients treated with radiotherapy from 1998 to 2008 and followed for a median of 5.9 years were reviewed.
RESULTS: Kaplan-Meier estimates of freedom from selected endpoints at 5 years after treatment were: overall survival, 79%; cause-specific survival, 91%; local control, 90%; and freedom from distant metastasis, 76%. Seven patients (21%) had eventual abdominoperineal resection or lower anterior resection, four patients had local recurrence, and three patients had incomplete treatment or poor margins. T3 lesions clinically staged by EUS were a predictor of local failure (P=0.0110), but not distant metastasis (P=0.35). Patients with either a pathological or clinical T3 lesion did not have a significantly greater rate of metastasis (P=0.096). Patients who were downstaged did not have a significantly different rate of local recurrence or metastasis. Patients who experienced a complete pathological response did not have a significantly different rate of local control or distant metastasis.
CONCLUSION: Patients with early-stage rectal lesions who undergo preoperative or postoperative radiation and TAE have similar outcomes to those who undergo abdominoperineal resection; local recurrence was higher for patients with T3 lesions when both were compared. Abdominal surgery should be considered for these patients. TAE is reasonable when patients are unwilling or unable to tolerate the morbidity of traditional transabdominal surgery.

Entities:  

Mesh:

Year:  2012        PMID: 22997356      PMCID: PMC3494544          DOI: 10.3121/cmr.2012.1072

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  15 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

3.  Transanal endoscopic versus total mesorectal laparoscopic resections of T2-N0 low rectal cancers after neoadjuvant treatment: a prospective randomized trial with a 3-years minimum follow-up period.

Authors:  E Lezoche; M Guerrieri; A M Paganini; G D'Ambrosio; M Baldarelli; G Lezoche; F Feliciotti; A De Sanctis
Journal:  Surg Endosc       Date:  2005-05-04       Impact factor: 4.584

4.  Preoperative radiotherapy alone or combined with chemotherapy followed by transanal excision for rectal adenocarcinoma.

Authors:  Kenyon Meadows; Christopher G Morris; W Robert Rout; Robert A Zlotecki; Steven N Hochwald; Robert D Marsh; Edward M Copeland; William M Mendenhall
Journal:  Am J Clin Oncol       Date:  2006-10       Impact factor: 2.339

5.  Anterior resection for rectal cancer with mesorectal excision: a prospective evaluation of 622 patients.

Authors:  Wai Lun Law; Kin Wah Chu
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

6.  A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy.

Authors:  G Lezoche; M Baldarelli; Mario Guerrieri; A M Paganini; A De Sanctis; S Bartolacci; E Lezoche
Journal:  Surg Endosc       Date:  2007-10-18       Impact factor: 4.584

7.  Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis.

Authors:  Leonard L Gunderson; Daniel J Sargent; Joel E Tepper; Norman Wolmark; Michael J O'Connell; Mirsada Begovic; Cristine Allmer; Linda Colangelo; Steven R Smalley; Daniel G Haller; James A Martenson; Robert J Mayer; Tyvin A Rich; Jaffer A Ajani; John S MacDonald; Christopher G Willett; Richard M Goldberg
Journal:  J Clin Oncol       Date:  2004-04-05       Impact factor: 44.544

8.  Quality of life after surgery for rectal cancer with special reference to pelvic floor dysfunction.

Authors:  P Varpe; H Huhtinen; A Rantala; P Salminen; P Rautava; S Hurme; J Grönroos
Journal:  Colorectal Dis       Date:  2011-04       Impact factor: 3.788

9.  Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience.

Authors:  M Guerrieri; M Baldarelli; L Organetti; F Grillo Ruggeri; G Mantello; S Bartolacci; E Lezoche
Journal:  Surg Endosc       Date:  2008-06-14       Impact factor: 4.584

10.  Impact of transanal endoscopic microsurgery on functional outcome and quality of life.

Authors:  P G Doornebosch; M P Gosselink; P A Neijenhuis; W R Schouten; R A E M Tollenaar; E J R de Graaf
Journal:  Int J Colorectal Dis       Date:  2008-04-01       Impact factor: 2.571

View more
  1 in total

1.  Neoadjuvant therapy followed by local excision and two-stage total mesorectal excision: a new strategy for sphincter preservation in locally advanced ultra-low rectal cancer.

Authors:  Ting Wang; Jianping Wang; Yanhong Deng; Xiaojian Wu; Lei Wang
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-01-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.